CareDx, Inc. $CDNA Stock Holdings Lessened by New York State Common Retirement Fund

New York State Common Retirement Fund lessened its stake in shares of CareDx, Inc. (NASDAQ:CDNA) by 79.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 16,339 shares of the company’s stock after selling 64,175 shares during the period. New York State Common Retirement Fund’s holdings in CareDx were worth $238,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Next Century Growth Investors LLC raised its holdings in CareDx by 309.4% during the 2nd quarter. Next Century Growth Investors LLC now owns 1,125,454 shares of the company’s stock worth $21,991,000 after buying an additional 850,580 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in shares of CareDx by 40.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,740,064 shares of the company’s stock worth $25,301,000 after acquiring an additional 503,136 shares in the last quarter. SG Capital Management LLC acquired a new stake in shares of CareDx during the second quarter valued at approximately $6,171,000. Ophir Asset Management Pty Ltd lifted its position in shares of CareDx by 17.0% in the 2nd quarter. Ophir Asset Management Pty Ltd now owns 1,892,994 shares of the company’s stock valued at $36,989,000 after acquiring an additional 274,625 shares in the last quarter. Finally, Bamco Inc. NY boosted its stake in CareDx by 11.2% in the 2nd quarter. Bamco Inc. NY now owns 2,435,657 shares of the company’s stock worth $47,593,000 after purchasing an additional 245,651 shares during the period.

Insider Activity at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total transaction of $407,964.80. Following the sale, the chief executive officer owned 597,405 shares of the company’s stock, valued at approximately $12,641,089.80. This trade represents a 3.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 29,636 shares of company stock valued at $625,949. 4.40% of the stock is currently owned by company insiders.

CareDx Price Performance

NASDAQ CDNA opened at $19.72 on Thursday. CareDx, Inc. has a fifty-two week low of $10.96 and a fifty-two week high of $25.55. The stock’s 50-day moving average is $19.70 and its two-hundred day moving average is $16.28. The firm has a market cap of $1.01 billion, a P/E ratio of 16.57 and a beta of 2.51.

Analyst Upgrades and Downgrades

CDNA has been the topic of several recent analyst reports. Wells Fargo & Company boosted their target price on shares of CareDx from $14.00 to $18.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of CareDx in a research report on Monday, December 29th. BTIG Research increased their price objective on CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Zacks Research raised CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Finally, Craig Hallum lowered shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 price target for the company. in a research report on Tuesday, January 6th. Three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $26.67.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.